Shingles vaccine linked to 24% lower dementia risk
- The Shingrix shingles vaccine is linked to a 24% lower risk of dementia in adults aged 66 and older over a four-year period based on a study of over 500,000 people in skilled nursing facilities.
- Among vaccinated individuals, 18.8% developed dementia compared to 24.6% of unvaccinated participants, suggesting one dementia case may be prevented for every 17 vaccinated people.
- Researchers analyzed Medicare claims and electronic health records using target trial emulation methods to adjust for health differences.
- Although the observational study cannot prove causation, researchers suggest potential neuroprotective effects of the vaccine and recommend randomized clinical trials for confirmation.
35 Articles
35 Articles
Shingles vaccine found to lower risk of heart diseases, strokes
A Nature Medicine study found lower cardiovascular burden in older adults who received Shingrix instead of the older live shingles vaccine. The findings have sharpened interest in benefits beyond shingles prevention, though trials are still needed to confirm any direct effect.
The benefits of the Shingrix vaccine, given in two doses, could be comparable to those of daily treatment with blood pressure medications, say researchers. The current vaccine against the zoster zone seems to significantly reduce the risk of myocardial infarction and stroke, according to scientists, who claim that it could contribute to preventing ...
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium




























